| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC8865 | RG-7112 Featured | RG7112 (RO5045337) is an orally bioavailable and selective p53-MDM2 inhibitor. |
|
| DC10389 | RIPA-56 Featured | RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1) with an IC50 of 13 nM. |
|
| DC8467 | RO8994 Featured | RO8994 is a potent and selective spiroindolinone MDM2 inhibitor for cancer therapy. |
|
| DC9746 | RSL3 Featured | RSL3 is a ferroptosis activator in a VDAC-independent manner,exhibiting selectivity for tumor cells bearing oncogenic RAS. |
|
| DC12279 | S55746 hydrochloride (BLC201 (hydrochloride)) | S55746 hydrochloride is a potent, orally active and selective BCL-2 inhibitor, with Kis and Kds of 1.3 nM, 520 nM and 3.9 nM, 186 nM for BCL-2 and BCL-XL, respectively. S55746 hydrochloride has antitumor activity. |
|
| DC12163 | S55746 (BLC201) Featured | S55746 (BLC201) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 (BLC201) has antitumor activity with low toxicity[1]. |
|
| DC10137 | S63845 Featured | S63845 is a potent and selective myeloid cell leukemia 1 (MCL1) inhibitor; binds human MCL1 with a Kd of 0.19 nM. |
|
| DC8444 | Sabutoclax Featured | Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively. |
|
| DC9506 | SJ-172550 Featured | SJ-172550 is the first MDMX inhibitor with EC50 of 0.84 uM; binds reversibly to MDMX and effectively kills retinoblastoma cells in which the expression of MDMX is amplified. |
|
| DC8599 | SP 141 Featured | SP 141 is a cell-permeable inhibitor of Mdm2 (Ki = 28 nM). |
|
| DC10964 | SW063058 | SW063058 is a small molecule that selectively disrupt Beclin 1/Bcl-2 binding as compared to Bax/Bcl-2 and Bim/Bcl-2 binding and induces autophagic flux at concentrations with minimal cytotoxicity.. |
|
| DC10965 | SW076956 Featured | SW076956 is a small molecule that selectively disrupt Beclin 1/Bcl-2 binding as compared to Bax/Bcl-2 and Bim/Bcl-2 binding and induces autophagic flux at concentrations with minimal cytotoxicity. |
|
| DC7314 | Tenovin-3 Featured | Tenovin-3 is a small molecule activator of p53 transcriptional activity. |
|
| DC5005 | tw-37 Featured | TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM, respectively. |
|
| DC7950 | UMI-77 Featured | UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family. |
|
| DC12064 | VU0661013 Featured | VU661013 is a potent and selective MCL-1 inhibitor. |
|
| DC10373 | WEHI-345 Featured | WEHI-345 is a potent and selective inhibitor of RIPK2, with IC50 of 0.13 μM. |
|
| DC9504 | YH239-EE Featured | YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent |
|
| DC4119 | YM155 Featured | YM155 is a potent IAP (inhibitor of apoptosis proteins) inhibitor for survivin with IC50 of 0.54 nM. |
|
| DC12350 | AMG-176 | AMG-176 is a potent, selective and orally bioavailable MCL-1 inhibitor, with a Ki of 0.13 nM. |
|
| DC5080 | Belnacasan (VX-765) Featured | VX-765 is a novel Caspase-1 inhibitor with an IC 50 of 0.8nM being investigated for the treatment of epilepsy, currently being developed by Vertex. |
|
| DC10851 | PK11000 Featured | PK11000 is an alkylating agent, and stabilizes the DNA-binding domain of both WT and mutant p53 by covalent cysteine modification, without compromising DNA binding. |
|
| DC28030 | PTC596 Featured | PTC596 is an orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor. PTC596 targets BMI1 expressed by both tumor cells and cancer stem cells (CSCs), and induces hyper-phosphorylation of BMI1, leading to its degradation. PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells. |
|
| DC28103 | F1324 TFA | F1324 TFA is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC50 of 1 nM. F1324 TFA exhibits binding t1/2 value of 441 s and has strong inhibition activity against BCL6 PPI. |
|
| DC28104 | F1324 acetate | F1324 acetate is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC50 of 1 nM. F1324 acetate exhibits binding t1/2 value of 441 s and has strong inhibition activity against BCL6 PPI. |
|
| DC28151 | PETCM | PETCM is an activator of caspase-3 and acts as an cytochrome c (cyto c)-dependent manner. PETCM promotes Apaf-1 oligomerization and induces cell apoptosis in HeLa cells. |
|
| DC28190 | β-Elemene | β-Elemene ((-)-β-Elemene; Levo-β-elemene) is isolated from natural plant Curcuma wenyujin with an antitumor activity. β-Elemene can induce cell apoptosis. |
|
| DC28318 | Z-Asp-CH2-DCB Featured | Z-Asp-CH2-DCB is an irreversible broad spectrum caspase inhibitor. Z-Asp-CH2-DCB also inhibits proteases with caspase-like activity. Z-D-CH2-DCB blocks the production of IL-1β, TNF-α, IL-6, and IFN-γ in staphylococcal enterotoxin B (SEB)-stimulated peripheral blood mononuclear cells (PBMC), and reduces SEB-1-stimulated T-cell proliferation in a dose-dependent manner. Z-Asp-CH2-DCB prevents SU5416-induced septal cell apoptosis and emphysema development. |
|
| DC28336 | Se-Methylselenocysteine Featured | Se-Methylselenocysteine, a precursor of Methylselenol, has potent cancer chemopreventive activity and anti-oxidant activity. Se-Methylselenocysteine is orally bioavailable, and induces apoptosis. |
|
| DC28441 | BTSA1 Featured | BTSA1 is a potent, high affinity and orally active BAX activator with an IC50 of 250 nM and an EC50 of 144 nM. BTSA1 binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to BAX leading to BAX-mediat |
|
